Janseen-Cilag has advised they will discontinue this range from mid-December 2016.
The product will remain funded until delisting 1 June 2016.
Stock may not be available for the entire period and Pharmac have not been successful in sourcing an alternative.
Patients will need to change to a different product.
The tables and oral liquid form of risperidone are still funded and available without Special Authority.